Current update on COVID-19 vaccines
Novel Coronavirus, also known as SARS-CoV-2, is an infectious disease that primarily affects the respiratory tract and gastrointestinal tract. The viral spread occurs through respiratory droplets produced while coughing and sneezing. Major vaccine targets for COVID-19 are spike protein, M protein, envelope protein, receptor binding domain, nucleic acids etc. Different mechanisms through which a vaccine can be developed to evoke an immune response include virus inactivated vaccine, live attenuated vaccine, subunit vaccines, virus-like particles, replicating and non-replicating viral vectors and nucleic acid-based vaccines. The mainstay of COVID-19 treatment is supportive and symptomatic therapy with dexamethasone, hydroxychlorquine and anti-viral agents like Darunavir, Ribavirin, Remdesivir, Interferons. Maintaining social distance, personal hygiene, use of N-95 masks aids in limiting the spread of the infection. There is a vital requirement for an ideal and potent vaccine with a favorable benefit-risk profile to evoke an immune response against SARS-CoV-2 infection. There are currently 11 approved vaccines in the market of which the Pfizer/ BioNTech vaccine have produced the most efficacy (95%), followed by Moderna (94%), Sputnik (91.6%), Covaxin (90%), Janssen (90%) and Astra Zeneca (70%). Vaccine hesitancy, vaccine-related adverse reactions and the high cost of the vaccine can be a major barrier to public acceptance and global access to the vaccine.
Keywords:COVID-19 Vaccines, Virology, Platform Technologies, SARS-CoV-2, Spike Protein, Vaccine Safety
Baden, L. R., Sahly, H. M. E., Essink, B. 2021. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine, 384(5):403– 416.
Chan, S. K., Du, P., Ignacio, C., Mehta, S., Newton, I. G., Steinmetz, N. F. 2020. Biomimetic Virus-Like Particles as Severe Acute Respiratory Syndrome Coronavirus 2 Diagnostic Tools. ACS Nano, 15(1):1259–1272.
Chung, Y. H., Beiss, V., Fiering, S. N., Steinmetz, N. F. 2020. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design. ACS Nano, 14(10):12522–12537.
Corey, L., Mascola, J. R., Fauci, A. S., Collins, F. S. 2020. A strategic approach to COVID-19 vaccine R and D. Science, 368(6494):948–950.
Ella, R., Vadrevu, K. M., Jogdand, H., Prasad, S., Reddy, S., Sarangi, V., Ganneru, B., Sapkal, G., Yadav, P., Abraham, P., Panda, S. 2021. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. The Lancet Infectious Diseases, pages 1–10.
Frederiksen, L. S. F., Zhang, Y., Foged, C., Thakur, 2020. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Frontiers in Immunology, 11.
Ghorbani, A., Zare, F., Sazegari, S., Afsharifar, A., Eskandari, M. H., Pormohammad, A. 2020. Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach. New Microbes and New Infections, 38:100786.
Hageman, J. R. 2020. The Coronavirus Disease 2019 (COVID-19). Pediatric Annals, 49(3):e99–e100.
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N. 2020. An mRNA vaccine against SARS-CoV-2-preliminary report. New England Journal of Medicine, 383:1920–1931.
Kaur, S. P., Gupta, V. 2020. COVID-19 Vaccine: A comprehensive status report. Virus research, page 198114.
Le, T. T., Andreadakis, Z., Kumar, A., Román, R. G., Tollefsen, S., Saville, M., Mayhew, S. 2020. The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery, 19(5):305–306.
Lederer, K., Castaño, D., Atria, D. G. 2020. SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. Immunity, 53(6):1281–1295.
Li, H., Liu, S. M., Yu, X. H., Tang, S. L., Tang, C. K. 2020. Coronavirus disease 2019 (COVID-19): current status and future perspectives. International journal of antimicrobial agents, 55(5):105951.
Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, S. 2021. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet, 397(10275):671–681.
Lundstrom, K. 2020. Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. Viruses, 12(11):1324.
Parasher, A. 2020. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgraduate medical journal, pages 1–9.
Polack, F. P., Thomas, S. J., Kitchin, N. 2020. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, 383(27):2603–2615.
Prub, B. M. 2021. Current State of the First COVID-19 Vaccines. Vaccines, 9(1):1–30.
Raja, A. T., Alshamsan, A., Al-jedai, A. 2020. Current COVID-19 vaccine candidates: Implications in the Saudi population. Saudi Pharmaceutical Journal, 28(12):1743–1748.
Ramezankhani, R., Solhi, R., Memarnejadian, A. 2020. Therapeutic modalities and novel approaches in regenerative medicine for COVID-19. International Journal of Antimicrobial Agents, 56(6):106208.
Rawat, K., Kumari, P., Saha, L. 2020. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. European Journal of Pharmacology, 892:173751.
Sharma, O., Sultan, A. A., Ding, H., Triggle, C. R. 2020. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Frontiers in Immunology, 11:2413.
Silveira, M. M., Moreira, G. M. S. G., Mendonça, M. 2020. DNA vaccines against COVID-19: Perspectives and challenges. Life Sciences, 267:118919.
Swann, H., Sharma, A., Preece, B., Peterson, A., Eldridge, C., Belnap, D. M., Vershinin, M., Saffarian, S. 2020. Minimal system for assembly of SARS-CoV-2 virus like particles. Scientific Reports, 10(1):1–5.
Wang, H., Li, X., Li, X. 2020. Treatment and prognosis of COVID 19: Current scenario and prospects. Experimental and Therapeutic Medicine, 20(6):1.
World Health Organization 2014. Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation and monitoring. pages 1–136.
Xu, R., Shi, M., Li, J., Song, P., Li, N. 2020. Construction of SARS-CoV-2 virus-like particles by mammalian expression system. Frontiers in bioengineering and biotechnology, 8.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.